The valuation of pharmaceutical brands

Nick Liddell
Additional contact information
Nick Liddell: Interbrand

Chapter Chapter 2 in Brand Medicine, 2001, pp 27-44 from Palgrave Macmillan

Abstract: Abstract The investment community’s interest in the pharmaceutical industry has led to high stock market valuations for businesses that succeed in the sector. Such businesses have in the past amply repaid their investors, reflected in increased profits, dividends and share prices. The industry has relied for these profits on the ability of drug companies to pass on rising drug costs to the consumer in higher prices. This ability to charge high prices arises from the economic peculiarity of the industry.

Keywords: Discount Rate; Pharmaceutical Company; Intangible Asset; Trade Mark; Corporate Brand (search for similar items in EconPapers)
Date: 2001
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:pal:palchp:978-0-230-52251-0_3

Ordering information: This item can be ordered from
http://www.palgrave.com/9780230522510

DOI: 10.1057/9780230522510_3

Access Statistics for this chapter

More chapters in Palgrave Macmillan Books from Palgrave Macmillan
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().